[原 著] ATP 法を用いた非結核性抗酸菌の薬剤感受性試験の検討

164
ῌ῎
῏῍
ATP ῳQ̮̯ῺQ ῒQQQῩ̳Q̳QῒQQῩQ΅
̳̮QQ1)῎̮
Q1)῎ ̮῍Q1)῎Q῭ῨQ2)῎´ῠ
 2)῎ῖQ̮Q1)
1)
̯Q̯ ῶ ̲̲῟̲ῺQQQQ̲Ώ῔῾QQQ
2)
QῪ῕̳QQ̳Q̲QQ῵QQQQ῿ῶ̲
῔ ΐ 16 ̱ 4 Q 8 ̱Q̲῍ ΐ 16 ̱ 9 Q 7 ̱QQ῕
῔QῚQ̯ῲῨ Q̯` adenosine triphosphate (ATP) ῳ῔῾ῶQῤ῞̰̯`῞ῥῨῬ΅
Nontuberculous Mycobacteria (NTM) Ῡ̳Q̳QῒQQῳQῖῌ̯ῧ ῔ATP ῕ ῳ῿ῶ
̯῍ ̯ῩQΊ̰Q΅ῧ῭̰ῨΏQΏ̯QQ ῔MB ῕ ῥῩΌ Q΅ῳ ATCC ῼQ̳ 4 ̳ῥQ
Q῿Q̳ 45 ̳ῳQ̮ΰQῡ̯ῌ ATP ῞̰ Ῠῢ̮ΰ̰Q΅ῩQ̲῍ ῙQQ̰Q̲Ῠΰ῍ 30
῿̳QQ῍ ῥQQQ̰ 60̮ Ῠΰ῍ 10 ῿̳Ὶ̰Ύῤ̮`῞ῥῚ ̱̯῰̯ῌ ATP ̰̱̱ῐ̱
ῳ 5 ̱̳ῴQQῨ Relative light units (RLU) ratio ῳ῞̰̯῍ 7 ̱̳ῴQῩ MB ῥΌ Q΅
̯̯ῌ streptomycin, ethambutol, kanamycin, isoniazid, levofloxacin, ethionamide, amikacin Ῡ 7 ̳QῩῶῷQῒῢῳ RLU ratio̮0.1, rifampicin ῘῬ̰ clarithromycin ῳ RLU ratio
̮0.03 ῥ̯̯ ATP ῥ῍ MB ῥῩῸΰQ̰ Mycobacterium kansasii ATCC 12478 ̰
84.4̮ ῥΎΎ̰̮ῢῤ̮ῡ̯ῪῩῩ῍
̯ῩῼQ̳ 3 ̳Ῠῢ̮ΰ̰ 97.8ῑ100̮
῔4 ̳ῤ̰
95̮῕ ῥQQῧQ̲Ὶ`῭῰̯ῌ ̰̯QQ῿Q̳Ῠῢ̮ΰῪ Mycobacterium intracellulare:
92.2̮, Mycobacterium avium: 97.2̮, M. kansasii: 100̮ ῤ῍ Ὶ̳ῤ̰ 95.3̮ ῥQQῧῸΰQ
ῳQ̯̯ῌ ̱QῬ΅ ATP ̰ NTM Ῡ̳Q̳QῒQQῥ̯ΰQQῧ ῤ̮`ῥ´̲̯῰̯ῌ
Key words: nontuberculous mycobacteria (NTM), adenosine triphosphate (ATP), minimum inhibitory concentration (MIC), bioluminescence
ῲῚQῩῺQ ῒQQQ (nontuberculous myco-
QQQQ̯Q̱Ό̲̰ 2003 ̱ 4 QῨ ῒ̱ῺQ ῒQ
bacteria; NTM) QῩ̳ 70̮ ̰ Mycobacterium
QQQ῎ῡῨ̳̯`Q῾ῌ2003 ̱ΐ ῳ̰Q̯ῌ̯ῧ
avium complex (MAC) ῨῬ`ῪῩῤ̯῜̰̱Ῠ̳ῒ
`῎ῡQQῳQΐ̯̯1)ῌ MAC Q̰QQῩ̯̰ΰῚ̳
̲ ῳQΐ̯`̱ MAC Qῤ̮`ῌ ῞῰̰ῤ MAC Q
QQQῩ̯Qῥῧ`ῲ῝ῤ̰ῧ̮ῥῩQῗῚῲῚQῤ
̰ῩQῒ̱Q ῍ Q̳Q ῧQ῍ ̱Ῐ῵Q῍ ῐ̱῍ Q
̰ῸῸ̰ῤ̮`Ὶ῍ ̳Qῳ̮Q̰ῨQQ̯Ῥῖῥ̯`
Qῒ̲ ῧῦῩ̱ῨQQ̰Q ῳQ̯`̳QῨ 2 Q
QQῪ̯ῠ̮ῨQ῜ῧῡΰ̮`ῌ ̯Ῑ̯ῧῚ῭ MAC
̰Ῠ̳ῗ̯̯ῥQῗ῭῰`QQῚ̯Ῑῡ̯Ὶ῍ QQῤ
̰Q Ῠ̯Ῥ̯Ῑ῭ῧ` ̳ῳQ̯῍ QQ ̳ΎQ
̰QΊQ̳Ῡ῰Ῠῧ̮ῤQ̱ῩQῒῨῶQ̯῍ ̯ῶῒ
Q̳Ῠ̯̯ΰ̰̳QῒῳQ̯̯̰῍ ̳QῨῬ`̱̳ῗ
ῩQQ̮ΎQ̳Q ῧῳQ̯QQῚQ῝̯ΰ̮`ῌ
QΎ AIDS ̳QῤῩῚ῏̱Qῒ̳ῗQ̰Q̰ΰῳQ
MAC QῩ῎ῡ̰Q QῩ῎ῡῥ̰ῴῧ΅QῩQQῩ
ῒῤ̮`ῌ ̰̯ MAC ῨQ̮ῤ̯῜QQ̯῰` Myco-
̰ῤ̰̲Q῿ῤ̮`ῌ ῞Ῡ̯̰̱̳Q ̲ ̲Ὼ̰Q
bacterium kansasii Ὺ 1997 ̱῟῱Ῥ΅Qῦῧ῝̲Q
QῨ̮΅῍ MAC QῨΌ̰ΎΎQ̱῜Ῡ̳QῚ̯̮ῥ
ῦQQQ̮῏ (̮565῍0871) ̯Q̲ῑ̰QQ̰Q 2῍15
̯Q̯ ῶ ̲̲῟̲ῺQQQQ̲Ώ῔῾
QQQ
̳̮QQ
TEL: 06῍6879῍6680
FAX: 06῍6879῍6683
E-mail: [email protected]
ac.jp
36 ̱̳QQΏ῔῾ QQ Vol. 14
No. 3
2004.
̯῰ΰ̮`ῌ M. kansasii ̰Ό ̰῱QῚQ῜῍ QΊ
Q̳Ῡῧ̮QQ̱ῨῪQ QQῩ̲ ῳQ΅Ύ̯̮
Ὶ῍ rifampicin (RFP) ῳῤQῥ̯`̲ Q Ῠ̯̯ΰ
QQῧῷῼῳQ̯῞ῥῙ῭ RFP ῳ̰̯̰ῥ̯` Q
QQ̳Ῡ̳QῒQQῳQQ̯`῞ῥῚQQῥ̯῰ΰ̮
`ῌ QQ῍ NTM QῨ̯̯QQQ̲ῚQ̯ῤΊ`QQ
̳ῥ̯ΰ clarithromycin (CAM)῍ azithromycin ῧῦ
ATP ῳΎΌ̮̯̰QQQQQQῤ̱QQQQQQῤQ̯
ῤΌ̲ῐ̲῱ ̲῭ῸQQQ̱̰῍ Ό̲ῐ῰Ὼ Q
165
῝Ί̯ῌ
ATP ῚQῳ
QQ̱῍ Ῥ̲Ὼῲ῾ῳ̱Ὸ῍ RFP ῢῡῤ̱QῗQΌῚ
C.
Ὺ̯̮̰̯Ῡ῍ ῾Qῖ̰ῥῙῪ̰ῤ̱Qΰ̮῝̰Q῔
Q̮ῖ̰ῤ ATP ῚQῤQ̯ΰ̯̮̯ῥQ̳ῥ̯Ύ
ῢ̱QQQQQQῳῤQ̰ῗ̱ῨῪ̯̮̰ῌ
McFarland No. 0.5 ΰΊQΊ̯Q̳ΎΌ̮῍ ῚQQ̱
̰Q῭QQῤQ῔̳ῤ̯ῩΰQ̰ῚῪ̯ῲῳῤ̳̯
(benzalkonium chloride) Ύ 50 ml ῟QΊ῍ ῚQ̳̯
ΰ̰Q῭ῤ`῵῝̰ adenosine triphosphate (ATP)
ῥQ̳῍ 60῕, 70῕, 80῕ ̯῍ Ὶ̰ΰῚQQQῥ 0, 5,
̲Ύΐ῝ΊQQQΎΐ῝῝̰ῲῳῗ̮̰ῌ Ῑῤῲῳῥ
10, 15, 20 ΅ Q ̯ Q ῼ Ί ̯ Q ΰ Q ̳ ΰ ̱ Ί ̯ ῖ ̰
QQQῠ ATP ̲ῤQΰQῩ̯̲QῢῐQQQῗ̮
ATP ΐ῝ΎQ̯̯ῌ
̰῍ Ὶ̰ΰ῍ Ῑῤ̰QQ̲ῗQ̮̯ῩQῩ̯QQ̯̯
D.
ATP ΐ῝ῳ
ΐ῝Qῦῢῲῳ̯̮̰ῌ Ῑῤ ATP ̲ΐ῝ΰ̰̰̱Q
ATP ΐ῝ῳῥQQΰQΊ̯ ATP ῎Qῼῢ̰ῦΰ
QQQQQΎQ̮ῲῳῥ῍ ̳̰QQΰ̯̮̯ῥQ̯2)῍
ATP ῚQΎQ̯̯Qΰ῍ ̲῭῱ ̲ ῐῷΎ῿ῒΊ
̯3) ̰ῤ῰Q῍ Ῠ̯QQQΰ̯̮̯ῥQQ4)ῑ6) ̰ΰ
Q̳ΰ̱Ί̯ῖ̰῍ ̲῭῱ ̲ ῐῷ῾ῐ̱ῐ (LP-
̰̰῰Qῗ̮̰ῗ῍ NTM ΰῙῤῲῳΎΌ̮̯῰Qῥ
5000-kyokuto-1) ΰ̯Q̯῞ΰ̰QQ̱ ῒ῿̱ῼ`῾
Q̰Ὺῢ̮ῌ ̯Ῑ̯῍ Q῏ῥ ATP ΐ῝ΎΌ̮̯̱Q
῎῿̱ῼ`̲ῐ̱ΐ ΎQ΅`῿ΰ 100 ml ῟Q῝̰
QQQQQῳ ῒ Q ATP ῳῠ̲῝ΐ ῤQ῏Q̯ΎQ
ῠῠ̰ΰ̰Q̲ (Relative light units; RLU) Ύΐ῝Ί
̮῍ QΏῳῤ̰̲̳̮QQῳ ῒ Q MB ῳῠ̲῝ΐ ῠ
̯ῌ
ῤ̰QQ̯ΎQ̯̯ῌ
I . ῍ῐῌ῎῏
E.
̱QQQQQQ
1.
̰̲̳̮QQῳ̯ῤ MIC ΐ῝ ῒMB ῳΐ
MIC ΐ῝ΰῥ streptomycin (SM), ethambutol
A. QQQQ
(EB), kanamycin (KM), isoniazid (INH), RFP, levo-
QQQῠΊ̯ῥ American Type Culture Collec-
floxacin (LVFX), CAM, ethionamide (TH), amikacin
tion (ATCC) ̰QQῠΊ̯ M. avium ATCC 700898,
(AMK) ῤ 9 ̱QΎ 2 Ῠῥ̯QQQ ῒSM, EB, KM
M. avium ATCC 25291, M. kansasii ATCC 12478 ̮
ῥ 0.06ῑ128 mg/ml ῤ 12 ̮Q῍ INH, RFP,
̰ῦ Mycobacterium intracellulare ATCC 13950 ῤ 4
CAM ῥ 0.03ῑ32 mg/ml ῤ 11 ̮Q῍ TH, AMK ῥ
QΎΌ̮̯ῌ Ῠ̯῍ ῾Q΅´QῠΊ̯ῥ̮Q̮Q Q
0.5ῑ16 mg/ml ῤ 6 ̮Qΐ ΰΊQΊ̯ MIC ΐ῝Ό̲
ῬΎ῕Ὺ̳ΰ̯QQῤQQQῶΏQ̲ῖ̰΅´῎̯῝
ῐῷ̯̮̰´ ̱̲῵῱ NTM ῒQ̯Q̱QQΐ Ύ
ῚῪ̯ 45 QΎQQΊ̯ῌ ̯ῤῠῴῥ῍ M. avium 20
Ό̮̯ῌ
LVFX,
Q῍ M. intracellulare 20 Q̮̰ῦ M. kansasii 5 Q̯
ῌQQ̳ῤΊQῲῳῥ῍ 1̮ Q῍Ῡῖ̯ῩῺΊ̯ 4
̮̯̯ῌ ῢ̮῍ ῾Q΅´Qῤ̯῝ῥ DDH (DNAῌDNA
Q Q ῠ ῤ ̰ Q Q ῢ ̰ ῦ ΰ ῾ Q ΅ ´ Q Ύ Middle-
hybridization) ̲῭ῳΏ῱ῶ῾Ῥ ῒQ̯Q̱QQΐ ΰ
brook 7H9 broth ῩῖΰQ̳ῤ̮̯Ύ῍ ῧ῜ 530 nm,
̯Q̯̯ῌ
QQ̯ 0.03ῑ0.05 ῤQQΰῌQQ῍ 37῕ ΰ̯ 3ῑ5
B.
ATP ῎Qῼῳ
ῢQῩῺΊ McFarland No. 0.5 ῒQQ̯ 0.08ῑ0.10ΐ
῎QῼῤQ̯̯ῥ ATCC ̰QQΎ Middlebrook
QΰῑQΊ̯ῩῺ̳ΎΌ̮̯ῌ QΰῙῤῩῺ̳Ύ̱
7H9 broth Ῡῖ ῒ̲῭ῳ´ ̱῍ Q̯Q̱QQΐ ̯῎
QQ̲Qΰ̯ McFarland No. 0.5 ΰQQΰQQΊQ
ῩῺQ῍ Q̳ῥ̯Ύ McFarland No. 0.5 ῒῧ῜ 530
Ί̯ῌ Ὶ̰ΰ῍ ΊQΊ̯Q̳ 110 ml Ύ̱QQ̲Q 11
nm, QQ̯ 0.08ῑ0.10ΐ ΰΊQΊ̯Qΰ῍ Middle-
ml ΰQ̮ῴ̲ῐ´̲῰̱ῐ̯Q Q῍ ´ ̱̲῵῱
brook 7H9 broth Ῡῖ̯ 1/2, 1/10, 1/100 ΰQQΊ
NTM ῤQ΅`῿ΰ 100 ml ῞̯ῌQΊ῍ ̱ῐ῿ΎΊ̯
̯Q̳ΎΌ̮̯ῌ ῎Qῼῥ῎Qῼ̳ A (2-amino-2-
̲ ῐῷΎ 37῔1῕ ΰ̯ 7 ῢQῩῺQΰ῍ ῡQ῞ΰ
methyl-1,3-propanediol) ῠ῎Qῼ̳ B (adenosine
Q̰ ῗῤῩ̰Ὺῢ̮QQ̱Qῥ̯Ύ MIC ̮ῠΊ̯ῌ
ATP ΐ῝ΰ̰̰̱QQQQQQῳ ῒATP ῳΐ
phosphate deaminase) ΎQΌQΰQ Ί῍ Q̳ῤ
2.
ΰ̯̯΅`῿ΰ῎Qῼ̳ 50 ml Ύ῟QΊ῍ Q̳̯ 0,
ATP ΐ῝Όῤ̱QQῘ̲ ῐῷῥ MIC ΐ῝Ό̲
30, 60, 90, 120 ΅Q῱ῗΊ̯Qΰ ATP ΐ῝ΎQ̮῍
ῐῷῤQQ̱Qῠ̯῜ῥ̯ῠῢ̰̰̮ΰΊQΊ̯ῌ
ῩῖῙῤῷ´ῤ ATP ̰̰Qΰ̳QΎQῧ῝Q΅ΎQ
ῢ̮῍ ̲ ῐῷῥ ATP ΎQ῭̰Q̯ΐ῝῝̰̯Ῡΰ
QῚ῟̰Ῑῠῗ̯Ῐ̰ῖῤQ̯ΎQ̯̯ῌ ῢ̮῍ MIC
̲ ῭ῷ̲ ῐῷῠΊ̯ῌ ῌQQ̳ῤΊQῲῳῢ̰ῦ
ΐ῝ΌῤῩῖ ῒ´ ̱̲῵῱ NTM ´ ̱῍ Q̯Q̱
ΰῌQῲῳῥ MB ῳῠ̯ῸΰQ̯̯ῌ
QQΐ ῤ῎QῼQQῤQ̯ΰ̯̮̯ῥ 0῍ 30 ΅Q̯ΐ
ATP ῤΐ῝ΰ̰̰ MIC ΐ῝ῥ 5 ῢQῩῺQΰQ
ῢ̱῾Q̰Q῭QQQ Vol. 14
No. 3
2004. 37
QQQQ῎Q
166
Q῎QQQQ῎QQQQ῎ῶQ Q῎Q῍QQ
QΊ῝ῌ QQQQῠ̳Q ΌῨ̰῍ QQ῎Q̲ῠQῷ
QQQ̲̯῟̮̯ῠ 3 ̲̯ῧ̯ 10 Q̲̱Q̯QQ̯
̯ 30 Q̲̯Ί῍ QQQQῠ 60̮, 10 Q̲ῸῷΊ῝ῌ
ΰῤQQ̯̯̰Ῑ̯ῖῩ῍ ATP QQQ̳ῠ 60̮, 10
QQ̳῍ Qῷ̯QΊ῝̳̯ ATP QQ̰Q῞῝ῌ QQ
Q̲̯Ί῝ῌ
ῠ῍ RLU ratio ῒQQ̲QQῌ̰Ὺ`̯ RLU Q̰QQ
B.
Q̲ΎῲῬ῱ῐ`̰Ὺ`̯ RLU Q̯QΊ῝Qΐ ̰ 1.
QQ̲QQQ̳
ATCC QQ ̲̯̯ MB Q̯ ATP Q̯̱Q
῏
ῦ RLU ratio῕0.1, ῕0.03 ̯Q῟̯΅̰ῲῬ̯ Q̱
̯QQ̰Q῞῝ῌ ̯̮῍ ΎῲῬ῱ῐ`̰Ὺ`̯ RLU
῭῰ῐῬ̰ 7 Q̲Qῌ̳῍ MIC QQ̰Q῞῝ MB
Qῠ CAM ̰QῘ 8 QQ̯῟̮̯ῠQQQ̲ΎῲῬ
Q̯ Ό̯῍ 5 Q̲Qῌ̳̯ ATP QQ̰Q̮῍ RLU
῱ῐ`̰Ὺ` ῒ3 ̰Ὺ`ΐ ̯Q RLU Q̯Ί῍ CAM
ratio ̯̯QQ̰Q῞῝ ATP Q̯̯ Ό̯̱Q῏̰῍
̯῟̮̯ῠQ̳QQ pH ῗQQ̯̱̯̰῝ῦ CAM Q
QQῌ̯QΏῖῩῼ῏5 ῺQQQ̳̰Q̮̳QΊ῝ῌ
ΎῲῬ῱ῐ`̰Ὺ`̯ RLU Q̯Ί῝ῌ
̯̮῍ ̱Q῏ῠ῔1 ̲̱Qῠ QQ̱̯Ί῝ῌ Table 3
̯῍ MB Q̰῾Q̯Ί̯ ATP Q̯ RLU ratio῕0.1 ̮
II. ῍
Ῠῡ RLU ratio῕0.03 ̰QQ̯Ί῝QQ̯̱Q῏̰
ῌ
Q Ί ῝ῌ RLU ratio ῕ 0.1 ̰ Q Q ̯ Ί ῝ Q Q῍ M.
A. ATP QQQQ̯̳Q
Table 1 ̯῍ QQ῎Q̲̯̳Q Ό̰QΊ῝ῌ ῵
avium ATCC 700898 ̯῟̮̯ῠ INH ̯ 1 Ὼ 2 ̲Q
QQQ̯ ῵QQ̯̮̰ McFarland No. 0.5 ̯ 1/
Ῐῖ῞῝ῧ̯̯῍ QQ̯῟̮̯ῠ῜ῢ̯ ῔1 ̲̱Q̯
100 ̯ ῑ̯ῠQ̳ῑῠQῘ῍ RLU Qῠ 302ῑ506
̱Q῏ῠ 97.8̮ ̯̮῞῝ῌ ῥ῝ M. intracellulare
̯̮̰QQQ̯ῴ ̰ ῤ῜Q̳ῑ̯ῠ̯̮Ῑ̯῍ ATCC 13950 ̯῟̮̯ῧQQQ ῔1 ̲̱Q̯ῐQ̯
QQ῿̯ ῵QQ̯̮̰ 1/10, 1/2 ̯ῠ 30ῑ60 Q̲
̱Q῏̰QΊ῝ῌ M. avium ATCC 25291 ̯῟̮̯ῠ
Q῎̯ῳQΊ῝ RLU QῗQῩ̰̰Ῑ̯ῗ´QῚ̰
ATP Q̯̯Qῗ RFP, CAM ̯ 2 ̲̱Q̯Q̮Q̰Q
῝ῌ ῥ῝QQ῎̯Ῠ῞̯QQQ̯ ATP QQQ̯Q̳
Ί῝ῗ῍ Q 7 QQ̯῟̮̯ῠ ῔1 ̲̱Q̯̮῞῝ῌ M.
̯ῴ ̰Q̮̰QQ̯ RLU Qῠ῍ 72,074 ̯̮῞῝̯
kansasii ATCC 12478 ̯῟̮̯ῠ KM, AMK ̯ EB
ῗ 30 Q̲̯ 384 ̯QΌQ̯Q῎Ὶ̰̯̮̰Ῑ̯ῗ´
̯Q̮Q̰Q῜ Q̯̮̰ 84.4̮ ̯̱Q῏̯̮῞῝ῌ
QῚ̰῝ῌ Table 2 ̯ῠ῍ QQQ̳̯῟̮̯QΊ῝ῌ
RLU ratio῕0.03 ̯Ί῝QQῠ῍ M. avium ATCC
M. avium, M. intracellulare ̯῟̮̯ῠQῷ̰Q̮̯
700898 ̯῟̮̯ῠ EB ̯ LVFX ̯Q̮Q̰QΊ
60ῑ80̮ ̯ῠQ̳ῑ̯Qῠ̳Ῡ̰̯ῖ῞῝ῗ῍ M.
88.9̮ ̯̱Q῏̯̮῞῝ῌ M. avium ATCC 25291 ̯
kansasii ̯῟̮̯ῠῷQῗQῘ̯̰̯ RLU QῗQῘ
῟̮̯ῠ῍ RLU ratio῕0.1 ̯Q̮Q̯̮῞῝ RFP,
̯̰ Q̯̮̰῍ 60̮ ̯QῧQ̮ RLU Q̰QΊ῝ῌ
CAM ῗQ̮̱Q῏̰QΊ῝ῌ ΊῖΊ KM ̯ AMK ῗ
Table 1.
E#ect of treatment time on the exogenous ATP.
Treatment time (min)
Dilution of organisms
suspension
0
30
60
90
120
M. avium ATCC 25291
blank
1/100
1/ 10
1/ 2
95
265
2636
13052
48
329
3981
26015
41
302
4129
25566
49
292
3779
26225
76
345
4412
30611
M. intracellulare ATCC 13950
blank
1/100
1/ 10
1/ 2
165
329
1774
15867
51
506
3987
40746
54
499
4462
44716
46
476
4133
54015
114
461
4313
57430
M. kansasii ATCC 12478
blank
1/100
1/ 10
1/ 2
155
306
1284
18574
50
414
3176
22077
43
506
2720
24503
41
399
3219
24090
117
377
3382
23905
BrothMIC NTM
blank
72074
384
NT
NT
NT
Strain
NT: not tested
38 QQῒQQQQ̲QQ Vol. 14
No. 3
2004.
ATP QῤQΐ̮QῪῩ̲῱̱̰῟Q̱̰ῷ̲ῴ῭῟Ύ Table 2.
167
E#ect of the temperature and incubation time on the extraction of ATP from nontuberculous
mycobacteria.
Extraction time (min)
Strain
Temperature
0
5
10
15
20
M. avium ATCC 25291
room temperature
60ῐ
70ῐ
80ῐ
5643
5643
5643
5643
7909
26090
24440
26967
8949
26223
23807
26795
9178
23592
28471
25016
9483
30892
25906
24740
M. intracellulare ATCC 13950
room temperature
60ῐ
70ῐ
80ῐ
972
972
972
972
7359
15368
16982
18823
7467
17435
18784
18386
7323
16998
17432
17160
7773
17525
18888
18246
M. kansasii ATCC 12478
room temperature
60ῐ
70ῐ
80ῐ
661
661
661
661
1125
8756
6249
5945
1321
8608
7178
5945
1245
8730
5938
5441
1211
9305
6579
5472
2 ̰ῥ̲῟ῳ ῤῶ̮̮Ί῔ῠῦ Q̯ ῔ῗ̮ῌ M.
῾ 8 Q̱̯῎1 ̰ῥ̳Ὶῒῗ̮ῌ M. kansasii ATCC
kansasii ATCC 12478 ῞ῘΐῙ̯ RLU ratio῏0.03
12478 ῞ῘΐῙ̯῍ ATP QῚ KM, AMK Ί EB ῕
Ί̮̮Q῕ RLU ratio῏0.1 Ί̮̮̯ῡ̯ῦ Q̯ῳ
MB Q῞̳̮ ΐ ῤῶ̮῍ ῦ Q̯ 84.4ῑ Ί ̮῍
̮῍ KM ῤῺΐ̮ 8 Q̱Ὶ ῎1 ̰ῥ̳Ὶῒῗ̮ῌ M.
̲Q̱ῤ RLU ratio῏0.03 Ὶ̳ ̮̮Ί̮῟ 97.8ῑ
intracellulare ATCC 13950 ῞ῘΐῙ̯ LVFX Ὶ 1
̯ῡ ΐῦ QῚῒῗ̮ῌ M. intracellulare ATCC
Ῠ 2 ̰ῥ̲ῤῶ̮̯῟῟῍ RLU ratio ῤ῜ῖῠῚ̳ 13950 Ὶ̯῍ ̮̯Ῑ῟Q̱Ὶ ATP QΊ MB Q̯ ῎1
̮Ῑ̯ῳΐῦ Qῤῶ̮̮ῌ
̰ ῥ ̳ Ὶ Q ῰ ῝ ῦ Q ῤ ῶ ̮ ̮ῌ Q Ό ̰ 4 ̰ Ὶ ̯
QΌ̰ 4 ̰ῤQ̱Q῞ RLU ratio῏0.1 Ὶ῟ῦ Q
ῤῬῙ̯ῢΊ῍ SM, TH Ί LVFX ̯ 100ῑ, EB Ί
INH ̯ 95ῑ ῚQ῰῝ῦ QῚῒῗ̮ῌ AMK Ί KM
95ῑ ῟ῦ QῚῒῗ̮ῌ
2.
QῼQQ̰Ὶ῟ MIC QΊ ATP Q῟ῦ QΊ
MIC QQ
̯ 85ῑ Ί̯̯ ΐ̰`῞ῒῡ῍ CAM Ί RFP ῞Ῐΐ
Table 5 ῞῍ QῼQQ̰Ὶ῟ MB QΊ ATP Q῟Ύ
Ῑ ̯ 75ῑ ῟ ΐ ῦ Q Ὶ ῒ ῗ ̮ῌ RLU ratio ῤ
῟Ὺῧῤῶ̮̮ῌ RLU ratio῏0.1 ῤQ̲Ί̮̮̲
῏0.03 ῚῬῙ̯ῢΊ῍ CAM, TH ̯ 100ῑ, SM, INH
̱῞ M. avium ̯ 93.9ῑ Ίῳΐῦ Qῤῶ̮̮ῌ Q̱
Ί RFP ̯ 95ῑ ΊQ῰῝ῦ QῚῒῗ̮ῌ LVFX ̯
QῚ̯῍ RFP Ί CAM ῕QΌ̰Ί Q῞ ΐ ῤῶ
90ῑ, EB ̯ 85ῑ Ί̯̯ ΐ̰`῞ῒῡ῍ AMK ̯
̮̰`῞ῒῡ῍ INH ̯ 2 ̰ῥ̲ ΐ ῤῶ̮̰῕ 4
80ῑ῍ KM ̯ 70ῑ Ί ΐῦ QῚῒῗ̮ῌ Q̱QῚ
̰Ῥῠΰ̮ῌ RLU ratio῏0.03 Ὶ̳ ῤῲῗ̮Ί̮῟
ῬῢΊ CAM Ί RFP ῟ RLU ratio ῤ ῏0.03 Ί̮ῢ
ῦ Q ̯῍ MB Q ῞ ̳ ̮ ῳ ΐ ῤ ῶ ̮ ̰ ` ῞ ῒ ῡ
̮Ί῞̯ῡῦ Q῕̲´̮̮῕῍ EB, KM Ί AMK ̯
78.3ῑ Ί ΐ῕῍ RFP Ί CAM ῞ῘΐῙ̯ ῎1 ̰ῥ
΅Ώ̮ῢ̰`῞ῒῗ̮ῌ
̳Ίῦ Q̯̲´̮̮ῌ M. kansasii ῞ῘΐῙ̯῍
Table 4 ῞῍ MB QῚ 5 Ῠ̳Q̲ ̮̮Ί̮῟ MIC
RLU ratio῏0.1 Ὶ̯̲Q̱῕ ῎1 ̰̱ῥ̳Ὶῒῡ῍
QQΊ ATP QῚ SM, EB, KM, INH, LVFX, TH, AMK
RLU ratio῏0.03 Ὶ̳ ̮Ῑ̯ 1 ̰ῳ̮Ὸῢ̰`῞ῒ
῟ 7 Q̱῞ῘΐῙ̯ RLU ratio῏0.1 Ὶ̳ ̮῍ ̰̰
ῢ̯῟῟Q῰῝ῦ Qῤῶ̮̮ῌ M. intracellulare ̯
῞̯ῗῙQῦ Q῟῿̮Ῥῠΰ̮ RFP, CAM ῟ 2 Q
90.6ῑ Ί̯̯ ΐῦ QῚῒῡ῍ SM, KM, INH, RFP
̱῞ῘΐῙ̯῍ ̳ ῤ RLU ratio῏0.03 Ὶῲῗ̮Ί̮
Ί CAM Ὶ MB Q ῞ ̳ ̮ ΐ ῤ ῶ ̮ ̮ῌ ̮ ῔ ̮
῟ῦ Qῤῶ̮̮ῌ M. avium ATCC 700898 ῞Ῐΐ
RLU ratio῏0.03 Ὶ̳ ̮ῢΊῳ̮Ὸῢ̰`῞ῒῡ῍
Ῑ̯῍ ATP QῚ῟Ὺῧ῕ INH Ὶ 1 Ῠ 8 mg/ml ῤῶ
 ῞ EB ῞ῘΐῙ̯ RLU ratio῏0.1 ̳ Ὶ 1 ̰̱῞
̮῍ MB QῚ῟̲ ῞̳̮ ῔ῗ̮̯῟῟῍ ῾ 8 Q
̳ῗῙΐ̮῕῍ RLU ratio῏0.03 Ὶ̯ 3 ̰̱ῤῶ̮̯
̱̯ ῎1 ̰ῥ̳Ὶῒῗ̮ῌ M. avium ATCC 25291 ῞
῟῕ 20 ̰ 11 ̰ῚῬῠΰ̮ῌ ̮῔̮ CAM ῞Ῐΐ
ῘΐῙ̯῍ ATP QῚ RFP ῕ ΐ̰`῞ῒῢ̯῟῟῍
Ῑ̯̮̯Ῑ ῎1 ̰̱ῥ̳῟ ῤῶ̮῍ RFP ῞ῘΐῙ
̳QQῼQ̲Q̰̱῵ Vol. 14
No. 3
2004. 39
̯῜ῗ̮ῌῚ
168
Table 3.
῔ῌ̯῜Ῐ῕ῌ̮̯῟̮ῌῒ῞ ̯ῌ῝ῡΊ̮
Concordance rate of the ATP method when the Microdilution (MB) method for reference
strains is set as a basis.
Strain
RLU
ratio
Drug
0.1
Streptomycin
Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
M. avium ATCC 700898
0.03
M. avium ATCC 25291
0.1
0.03
M. kansasii ATCC 12478
5
1
Streptomycin
Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
Streptomycin
Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
0.1
0.03
Streptomycin
Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
No. 3
2004.
4
3
1
2
4
3
Streptomycin
Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
Streptomycin
Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
40 ̯ῠῢῖ̯Ῑ̯ΐ̮̮ Vol. 14
Discrepancy of MICs
Concordance
rate (ῑ)
῏῎3 ῎2 ῎1 0 ῍1 ῍2 ῐ῍3
1
5
1
1
3
5
3
1
2
1
5
2
5
2
2
3
4
4
4
1
2
1
1
1
1
1
4
1
3
4
3
1
3
2
4
1
1
1
3
1
1
3
4
1
1
1
97.8
2
1
88.9
1
1
1
5
3
77.8
2
1
1
1
1
3
3
3
3
2
1
1
3
1
4
1
2
1
2
1
1
1
5
1
1
3
4
75.6
1
1
1
3
5
4
1
4
2
4
1
4
5
3
1
4
5
5
4
5
4
4
1
84.4
1
1
1
97.8
ATP QῪQ̮῞Q´̱Q῾ ΏῡQ ῷ̳Q ̲ῡ̲Q
Table 3.
Strain
continued
Discrepancy of MICs
Concordance
rate (῕)
ΐῑ3 ῑ2 ῑ1 0 ῐ1 ῐ2 ῔ῐ3
RLU
ratio
Drug
1
2
1
4
0.1
Streptomycin
Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
Streptomycin
Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
1
M. intracellulare ATCC 13950
0.03
Ῠ 1 ῶῪQ̮̯ ῒ1 Ὸ ΅QῡQῪ̳Ὶ῞ῌ
169
2
1
2
1
4
3
4
1
5
5
3
4
5
4
5
1
3
5
4
5
4
5
100
4
97.8
1
Q̯ MB Q̯ῡ῰QQῢ 95.3῕ ̯Q̲̯̮̯῞ῌ Q
QQQQῶ 45 ῶῪQ Q̯ῡ῰QQῪ῍ RLU ra-
Qῶ̯ῡ M. kansasii ATCC 12478 ̯ῩῩ῰QQῢ
tio῔0.1 ̯̲̯ῦ̰̯ EM ̯ AMK ῢ 100῕, TH ̯
Q̮Ῠῡῡ῍ ῝ῡQῡQQῶ̮̰ΰQQQQῶ̯ῡ´
LVFX ῢ 97.8῕ ῡQ̲̯῰QQῪ̳Ὶ῞ῌ SM, CAM
ῳ̮̰῍ ATP Q̯ῡ 5 QΌQQ̯ῡQQῺQῢ SM,
̯ KM ῢ 91.1῕, RFP ῢ 86.7῕, INH ῢ 82.2῕ ̯Ῡ
EB, KM, INH, LVFX, TH, AMK ῡ 7 Q ῠ̯̮̯ῢ
ῩQ̮῰QQ̯̮̯῞῍ RLU ratio Ὺ ῔0.03 ̯̲̯
RLU ratio῔0.1 ῪQQ̯Ὶ῍ RFP. CAM ῢ RLU
ῦ ̰ ̯῍ CAM ῢ 100῕, RFP ῢ 97.8῕, SM ῢ
ratio῔0.03 ῪQQ̯QQΊ̰Ῐ̯̮QQ̯̮̰̯ 95.5῕, AMK Ῠ 93.3῕ ̯ Q ̲ ̯ ῰ Q Q Ὺ ̳ Ὶ῍
̰̰̰ῌ
LVFX ̯ TH ῢ 84.4῕, KM ῢ 82.2῕, INH ῢ 80῕
Tables 7῎8 ῠῢ῍ ̱̲QῪ῿̯῞QQQQῶῡ
̯ῩῩQ̮ῼ̲ῠ̮̰῍ EB ῢ 44.4῕ ̯Q̮῰QQ̯
̮῟῍ M. avium ̯ M. intracellulare ῡ MB Q̯ ATP
̮̯῞ῌ Q Qῠ̲̯Ῠ CAM ̯ RFP ῢ RLU ratio
Q̯ῡ MIC QQῪ̳Ὶ῞ῌ M. avium ῠ̯̮̯ῢQ̮
Ὺ ῔0.03 ̯QQΊ̰Ῐ̯ῠ̰̰῰QQ̮QQΊ̰Ῐ
MIC Ὺ̳Ὶ῞ῡῢ RFP, CAM ̯῍ Qῶ 2 mg/ml ΅ῲ
̯̮̳Ῑ̰῞ῌ
̯̮̰QῴQῷQ̯̮̰Ῐ̯̮Qῧ̰̰῞ῌ ̳̮̯
Table 6 ῠῢ῍ ̱̲QῪ῿̯῞QQQQῶῡ MB
LVFX ̮QῗQῶ 4 mg/ml ΅ῲ̯̮̯῞ῌ M. intra-
Q̯῍ ATP Q̯ῡ MIC QQῪ̳Ὶ῞ῌ ATP Q̯ῡQ
cellulare ῠ̯̮̯ῢ RFP, CAM ῡ MIC ῢQῗ῍ Qῶ
Qῢ SM, EB, KM, INH, LVFX, TH, AMK ῡ 7 Q ῠ
0.25 mg/ml ΅ῲ̯ ̮ῷQῼ̲̮Qῧ̰̰῞ῌ ̳̮
̯̮̯ῢ RLU ratio῔0.1 ῪQQ̯Ὶ῍ RFP, CAM ῢ
̯ LVFX ̮Qῶ 2 mg/ml ΅ῲῡQῴQQ̮ MIC ̯
RLU ratio῔0.03 ῪQQ̯Ὶ῞̯ῖῡ῰QQῪ̳Ὶ
̮̯῞ῌ
῞ῌ M. avium ῠ̯̮̯ῢ῍ INH ̯ TH ̯ῢ MB Qῠ
QῚ ATP QῢQ̮ῼ̲ῠῢ̮̰̮ 97.2῕ ̯Q̲̯
ῌ
῰QQῪ̳Ὶ῞ῌ M. kansasii ῢΊῤ̯ῡQ ̮ ῒ1
῾ ΏῡQ ῷ̳Q ̲Qῠ̯̮̯ῢ 1997 Qῠ´
῍
Ὸ ΅Q̯̮̰Q̲̯῰QQῪ̳Ὶ῞ῌ ῥ῞ M. kan-
̱Ώῡ ̲Q̮QQ´̱Q῵̱ῠQQῙ̰̯̮̰ῌ Ῐ
sasii ῡ MIC QQῠ̯̮̯ῢ RFP, CAM ̯῍ Qῶ
Ῐ̯Q῭Ῑ̰῞ ̲QῢQQQQῪQ̮̰QQQ̯̮
0.25 mg/ml ΅ῲ῍ LVFX ῠ 0.25 mg/ml ΅ῲ̯̮̯῞
̰῍ ´ῳῢQQ 4 ̳΅Q̯QQQQQῡΏῡQ`̮Q
̮ KM ῠῢ 8 mg/ml ΅Qῡ MIC Ὺ̳Ὶ῞ῌ M. intra-
Qῠ̯̯῞̳Q̯QQΊ̰Ῐ̯ῠ̯̯̯̮̰῍ ̳ΌῪ
cellulare ῠ̯̮̯ῢ ATP Q̯ SM, KM ̮̰ΰ INH
QΊ̰Qῢ̱QῙ̰̯̮̰῜῍ Ὶ̮Ῠ´̱Ώῠ̲QῙ
̮Q̮ῼ̲̮̮̰῍ ῰QQῢ 92.2῕ ̯ῩῩQ̮ῼ̲
̰῞Ῠῡ̯̮̯῞ῌ ῝Ῐ̯̰̰QQ̯Q̱̯Q ῷ̳
ῠ̮̯῞ῌ QQQQῶ̯̲QῪ῿̯῞ 45 ῶ̯ῡ ATP
Q ̲Q̯Ὶ̯῱QQQῪQ̮῞῍ MGIT Q7) ῏ῬΎ
QQQQQQQ῵ ̳ Vol. 14
No. 3
2004. 41
QQQ̳῎Q
170
Table 4.
 ῎QQQ̳῎̳QQQ῎῵Q Q῎QQQQ
Concordance rate of the ATP method when the Microdilution (MB) method for reference
strains is set as a basis.
RLU
ratio
MIC range of
MB method
( mg/ml)
M. avium
Streptomycin
ATCC 700898 Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
0.1
0.1
0.1
0.1
0.03
0.1
0.03
0.1
0.1
2ῌ4
4ῌ8
2
32ῌ῔32
0.06ῌ0.125
0.5
0.25
2ῌ8
1ῌ2
Streptomycin
Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
0.1
0.1
0.1
0.1
0.03
0.1
0.03
0.1
0.1
8
4ῌ8
8
῔32
2
2ῌ4
0.5
4ῌ8
4ῌ8
Streptomycin
Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
0.1
0.1
0.1
0.1
0.03
0.1
0.03
0.1
0.1
῔128
4ῌ8
4ῌ8
4ῌ8
0.25
0.25
0.125
1
2ῌ4
M. intracellulare Streptomycin
ATCC 13950 Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
0.1
0.1
0.1
0.1
0.03
0.1
0.03
0.1
0.1
0.25
1
0.25ῌ0.5
4ῌ8
῕0.03
0.25
῕0.03ῌ0.06
16ῌ῔16
῕0.5
Strain
M. avium
ATCC 25291
M. kansasii
ATCC 12478
Drug
Discrepancy of MICs
῕ΐ3 ΐ2 ΐ1
0
1
2
̮3
Concordance
rate (̮)
5
1
1
1
3
3
1
4
3
5
1
1
2
5
4
1
2
1
1
1
1
3
3
2
4
1
4
1
3
4
1
2
3
1
1
4
3
1
1
1
1
1
1
2
1
2
1
4
1
2
97.8
3
1
97.8
3
5
4
1
4
5
4
4
4
4
3
4
1
5
5
5
4
5
84.4
100
῱̱῎῰̰`Ὺ̱΅̱ῒ ῧῲ̱῭̱`Ύ MTB-1 Q8)
´QQQ ̯̮̰QQῴQ̲QQ9)ῢ̲̯̮̯QQ̯
ῑ῾QQQ̳̲ῒ ̮̰̮ῤQQQ ̰Q̮̯ Ὼ῿ΰ
̮̰ῲ̱῭̱`Ύ NTM ̰Q̮̯ MB Qῠ῍ Q῞Q Q Q Q ̳ ´ Q Q Q Q ̯ ̮ ̰ ̱ Ῥ ̱ ` Ύ MTB-SR
Q̳ΰQQῠῡ̰Ῠ̮ῢῳ̱ῐ῱̰̳Q῝QQ ῢ῿
ῑ῾QQQ̳̲ῒ ῗΌQ῜̰̯̮̰ῌ ῝ῖ῝ NTM ῢ̮
QQΰ ATP Q̰QQ῝῍ ΊΰQῖῩ MIC Q̰̲ῦ̯
̮̯ῤῨ̮ῧῙQQῴQ̲QQ̯̮̰ῲ̱῭̱`Ύ
ATP QῠΰQῷ̰Qῥ̯ῌ
NTM ῑ῾QQQ̳̲ῒ ῗQQῶῢQ̯̯̮̰ῗ῍ Q NTM ΰQ̳´QQQ ̰̳̮ῢ̮̯̰῍ QQQQ
Q ῧQQ̲QῗΏQ῜̰̯̮ῡ̮ΰῗ Q̯̮̰ῌ
̰QῚ̰̯ῦΰQQῠῡ̰ΰῤ῿ῴQQQQ̯̮̰ῠ
̯ Ί ̯ Ὸ ῏ ῤ NCCLS (National Committee for
Q̰̰̰ῌ ̲Q῟̰ῠῘῤQQQQ̲ΰ῿ῴ̰Q̮̰
Clinical Laboratory Standards) ΰQQ῝̯̮̰Q̳
Ίῠῗ Q̯̮̰῍ QQQQ̮̰̮ῤ῿ῴQQQQῢ
42 QQQQQQQῼQQ Vol. 14
No. 3
2004.
ATP ῠ῕ΰῒΐ̯̮̮῟ῗῚ̮῔ῢῘ̮῝῟Ίῖ῔̮̯
Table 5.
171
Concordance rate of the ATP method when the Microdilution (MB) method for clinical isolates
of M. avium, M. kansasii and M. intracellulare is set as a basis.
Strain
RLU
ratio
Drug
0.1
Streptomycin
Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
M. avium (N῎20)
0.03
M. kansasii (N῎5)
0.1
0.03
Streptomycin
Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
0.1
0.03
1
1
Streptomycin
Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
Streptomycin
Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
M. intracellulare (N῎20)
Discrepancy of MICs
Concordance
rate (ῑ)
῏῍3 ῍2 ῍1 0 ῌ1 ῌ2 ῐῌ3
Streptomycin
Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
Streptomycin
Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
4
3
1
1
1
8
1
5
10
9
4
8
9
2
11
17
15
6
7
10
10
8
16
2
9
4
6
5
14
11
11
7
7
1
6
3
2
2
1
3
1
3
1
1
1
3
4
1
1
1
4
3
2
1
1
1
1
3
5
5
3
4
2
4
2
3
3
5
1
4
4
4
3
2
2
5
1
7
11
3
7
10
3
5
11
19
9
5
15
12
8
17
15
5
12
3
13
12
15
4
10
14
15
3
3
1
4
7
1
1
2
93.9
2
2
7
2
9
8
2
1
4
6
6
7
10
3
13
1
5
78.3
3
2
3
1
100
1
1
3
1
1
97.8
1
2
3
90.6
1
3
6
2
2
3
8
3
5
4
11
1
1
87.8
3
̯ῡῤ῞̯̯̯̮Ῑ῜ Vol. 14
1
1
No. 3
2004. 43
QQQ̳῎Q
172
Table 6.
 ῎QQQ̳῎QQQQ῎ῴQ Q῎QQQQ
Concordance rate of the ATP method when the Microdilution (MB) method for clinical isolates
of M. avium, M. kansasii and M. intracellulare is set as a basis.
RLU
ratio
MIC range of
MB method
( mg/ml)
Streptomycin
Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
0.1
0.1
0.1
0.1
0.03
0.1
0.03
0.1
0.1
1ῌ32
4ῌ῔128
2ῌ32
4ῌ῔32
0.125ῌ0.2
0.5ῌ4
0.125ῌ2
4ῌ῔16
1ῌ16
Streptomycin
Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
0.1
0.1
0.1
0.1
0.03
0.1
0.03
0.1
0.1
4ῌ8
2ῌ4
8ῌ32
2ῌ4
0.125ῌ0.25
0.25ῌ0.5
0.125
1ῌ2
2ῌ8
M. intracellulare Streptomycin
(Nΐ20)
Ethambutol
Kanamycin
Isoniazid
Rifampicin
Levofloxacin
Clarithromycin
Ethionamide
Amikacin
0.1
0.1
0.1
0.1
0.03
0.1
0.03
0.1
0.1
0.5ῌ4
2ῌ32
0.5ῌ4
2ῌ῔32
῕0.03ῌ0.25
0.5ῌ1
0.06ῌ0.25
4ῌ῔16
῕0.5ῌ4
Strain
M. avium
(Nΐ20)
M. kansasii
(Nΐ5)
Drug
Ῡ̯̯Q QQῗQQ῝̰ῚῠῤῩῙQ̰̰̯̮̰ῌ
Discrepancy of MICs
῕ῒ3 ῒ2 ῒ1
0
1
8
1
5
10
6
4
3
9
2
11
17
15
6
14
16
11
8
16
1
2
2
3
1
3
5
5
3
4
2
3
2
3
5
1
7
11
1
7
7
3
5
11
19
9
5
15
12
10
17
15
4
1
2
1
3
4
1
4
3
1
2
̮3
Concordance
rate (̮)
97.2
6
2
2
100
2
1
3
92.2
1
3
Q̰̰̯ῌ
῜ῖῨ NTM ῢQ῝̰QQῤQ QῡQQῗQῡῙQ
QQ̰4)ῑ6) ῤ ATP Q̯ Ό ΰQQ̲QQQ ̰
QῡQQῗQῙ῍ ΰQQ´QQQῢῩ̯̯̳ Q
Q῜̯̮̰ῗ῍ QQῤ RLU ratio ̰ 0.5 ̯̳̯̯̮
ΰ̳ ´Qῢ̱̮ῗ̯̰ῨΰῠQ̰̰̰ῌ Ὶΰ̯ῧQ
̰ῌ ῶ῏ΰQῷ Q̰̳̯̯ NTM ῤ῍ Ό ῢQ῜
ῷΰ QQῢῤ῍ QQQQῢ ̰QQQQ῜῍ McFar-
̯QQῗQῙ῍ ῦ̯̯̰ῢQ̯̯ ATP QῨQ̮Ὶῠ
land No. 0.5 ̱QῢQQ῜QQQQ῾ΰQQΰQ̮ ῖ̰῍ QQ῜̯Q̰ῠ̰̮̰ῠ̮̮Ὶῠ̯ RLU ratio
̱̰῍ QQ̲QQQ ῢQ̮̯ῌ
ῤ ̮0.1 ̯QQ̰̳̯̯ῌ ῚΰQQ̲Q̯QQ̲̯ΰ
ATP QΰQQQ̲ῢ̯̮̯Qῷΰ Q̯ῤ 5 Q̲
Q̰̳̯̯ῠῚ̰ M. avium ATCC 700898 ῠ M.
ῠ῜̯ῗ῍ QQ̲̰Q̮̯ 3 Q̲QQ̯ΰ ATP Qῢ
intracellulare ATCC 13950 ῤQ̳ῡ̱QQ̰Q῜̯
Ῡ̰QQ̲QQQ ̯ῤ῍ ῭̱῰ῳῐῲΎῬῲΰQ῿
ῗ῍ M. avium ATCC 25291 ῤQ̮̱QQ̯̮̯̯ῌ
RLU Qῗ 10,000 ῢQ῟῞῍ QQ̰Q῝Q̳ῗQῙ Ὶΰ̲̰QQQ̯ MB QῠQΏ῝̰ῠ RFP, CAM ῗ
̰̰̯ῌ ̯ΰ ῵ῠ῜̯`ῐ΅ῐῤQ῜̯ῤ̮ῡ̮ῗ
2 ̲̱QΰQ̮Q̯̮̯̯ῌ ̯Ὶ̯ RLU ratio ̰Q̮
RLU ratio ῢῥ̰̯Ῐῗ ̰̰῍ 3 Q̲QQ̯ῤ MB
̯ MB Qῠΰ̱QQ̰ ̯ῠῚ̰῍ RLU ratio̮0.03
Qῠΰ̱QQῤ 60ῑ91.1̮ ῠQ̮ ῵ῠῡ̯̯ῌ
̯ MB QῠQ̳ῡ̱QQ̰Q῝ῚῠῗῺQΊ̰̯ῌ Ὶ
ATP Q̰Q̮̯ 3 Q̲QQ̯QQ̲QQQ ̰̳̮
ΰ ̳ῤ M. avium ῠ M. intracellulare ΰQQQQ̲
Q̳ῢῤ῍ Ί̰ῡ̰QQΰῸQ῍ QQQ ῍ QQQ
̯Ῠ ̰̰̰Ὶῠῖ̰῍ Q῜̯Q̲̰ RLU ratio̮
RLU ratio ̰̲ῧ̯ Q̰̳̮ῚῠῗQQ̯̮̰ῠ
0.1 ῠ RLU ratio̮0.03 ΰ 2 ῱Ὺ̱῰̯QQ̰̳̮Ὶ
44 QQQQQQQῼQQ Vol. 14
No. 3
2004.
ATP QΎ῍῕῟Q ´Q̳Q ῢQQ̲QQQ̳ῢ Q
Table 7.
173
Distributions of MICs of nine antibiotics obtained by Microdilution (MB) and ATP method
against clinical isolates of M. avium (Nῐ20).
Drug
Method
Streptomycin
MB method
ATP method
Ethambutol
MB method
ATP method
Kanamycin
MB method
ATP method
Minimum inhibitory concentration ( mg/ml)
ῒ0.06 0.125 0.25
0.5
ῒ0.03 0.06 0.125 0.25
Isoniazid
MB method
ATP method
Rifampicin
MB method
ATP method
Levofloxacin
MB method
ATP method
Clarithromycin
MB method
ATP method
3
ῒ0.5
Ethionamide
MB method
ATP method
Amikacin
MB method
ATP method
1
1
1
8
5
2
2
1
2
4
8
16
32
1
1
3
6
6
7
4
3
4
3
2
3
3
2
2
7
7
5
4
2
2
3
1
6
5
7
7
2
5
1
2
4
8
1
1
7
8
5
0.5
1
4
5
2
4
4
4
5
6
6
6
7
2
2
1
2
8
3
5
9
4
4
2
4
8
16
ῑ16
5
7
5
6
5
6
3
1
2
1
1
3
5
9
6
6
6
1
64
128 ῑ128
1
1
1
16
32
ῑ32
4
5
6
2
1
2
2
4
2
̯̯Ὶ῟ῌ RLU ratio Ύ̯ῢQ̯̯̰̮̰̮ῡ̯῕̯
῰Q῵̮῔̯̯̰QQῚῠ῕Ῐ̯̯Ὶ῟ῌ “trailing”
ΰ῍ ῿QΊ̰ ̲ῢ Q῵QQῢῴ῕ῡ̰̯̯Q̮ῠ
̳Qΰ῍ QQ̰11) ̰Qῦ̯῕̰̰̮ῡ῍ NTM ̯ΰ
Ὸ ΎQῗ̰̰ῢ̯QῪ̰̰ῌ QΏῢ Qῡ̮῕̯̰
MBC (minimum bactericidal concentration) ̯ MIC
M. kansasii ATCC 12478 ΰQ῵QQ̮Q῕Ῐ̯̮
ῢQ̮ῧ̯Ῥ̯ῢQQ̯ Ῡ̯Q῕Ῐ̯ῡ̰̰̯Ῑ̰
̰῍ RLU ratioΐ0.03 ̯Ὶ῟Q̮ RLU ratioΐ0.1 ̯
̯῕̰ῌ QΏῢ Q̯ RLU ratio Ύ ΐ0.03 ̯QQῚ
Ὶ῟̰̰̰ῶQΐ̮Qῖῠ̯῟̰ῢ̯QῪ̰̰ῌ Ῠ῟
῟QQῡ῍ QQῡ̰̯̯ΰ MB QῡQῚQ῕QΎQΊ
QQῡ̰̯̯ RLU ratio ΎQῖΊ̰Ῐ̯ῡ̰̯̯ῶ
̰ῢ̰῔̰῍ Q̲ῠQ῵῏QῙ̰̯῕̯̰Ὺ῜̮ῠQ
Qΐ̮QQῚ῟̮ῡ̯῕̯ΰ῍ QQ̰10)ῢ M. avium
QῢQQ̮῔̰̰ῢ̯QQῙ̰̰ῌ Ῠ῟QQ̰ῢQ
ῡQΊ̰̳ QῢQ῍Q̳῱`῏̱ῢQ̲ QῚ῟Q
Q12)ῡ̳̰̰̰̰̮ῡ MAC ῡΰQῶ ̲ῌῐῢQῑ
Qῡ̳̰̰̰̰̮ῡ῍ QQ῔̰῕ΰQQῢQQῡ̰̯
Qῢ̱ῠ̰ 3 QῢQῑQ̱̲̮QῒῙ̰῍ ῝ῢῲ̱
̯QQ Qῡῴ῕̮̳̰̰῍ RFP ̮̰ῥ CAM ῡQ
̱̱΅̮̰ῥ̲QQ῱`῏̱̮῝̰῞̰̱ῠ̰Ῐ̯̮
Ὶ̯ M. avium ΰ MIC QQ ̯ῢQQQῼQ῍̮Q
Q̰̰̯῕̰ῌ ̮QQ῔̮̰QQQQ̯QQQ῎Ὶ῟
Ῡ̰̰῍ QQQ̮῾Q̯῔̯῟Ῐ̯̮̰ ATP ῕ῢQ
MAC ̲̯ῢQQQQ̲QQ QΎQ̮QQῡΰ῍
Q̮Qῠῖ῍ RLU ratio QΎQῖ̯̰Ῐ̯ῡ̰̯̯
3 QῢQῑQ̱̲̮QQΊ̰Ῐ̯̰̳̮̰̰̰Ῐ̯̮
MB Q̯ῢῶQΐ̮QQῚ῟̰ῢ̯QQῙ̰̰ῌ
̰ “trailing” ̳Qῢῶῷῡῠ̰̰ῢ̯QῪ̰̰ῌ Ό῎
NTM ῢQQ̲QQ Qῡ̮῕̯῍ ῚῤῚῤ “trail-
ΰ Q Ώ ῢ   Q Q ῡ ̮ Q Q ῒ ̲ ῡ ̯ ῕ ̯ ΰ Middle-
ing” ̳Q̮̳̰̰῍ MIC QQQῡQ̮Ί̰Ῐ̯̮῔
brook 7H10 ̲QQQῡῺQQQῚ῍ QῒQ῎ΎQ̯
̰ῌ Ό῎ΰ MB Q̯ῢQQΎQ̮̯̮ῡΰ῍ Q̲ῠ ῟̳ῡQ̳ῡ῿Ὶ῟ῌ ῿Q ̲ῢQῑ QΎQ̯̯Q
Q῵Ύ῏QῚ῟QΎ MIC Q̯Ὶ῍ QQῠῳ̱̱῭̱
Q̲QQQ̳ΎΊ̰Ῐ̯ῡ̰̰̲QQ QQQῢQQ
QQ̮QQQQ̲QQ Vol. 14
No. 3
2004. 45
QQQ̳῎Q
174
Table 8.
῎QQQ ῎QQQQ῎ῴQ Q῎QQQQ
Distributions of MICs of nine antibiotics obtained by Microdilution (MB) and ATP method
against clinical isolates of M. intracellulare (N῕20).
Drug
Method
Streptomycin
MB method
ATP method
Ethambutol
MB method
ATP method
Kanamycin
MB method
ATP method
Minimum inhibitory concentration ( mg/ml)
̮0.06 0.125 0.25
0.5
1
2
4
3
4
8
8
7
5
2
1
9
8
5
5
2
4
10
9
7
5
0.5
1
2
4
8
4
7
4
7
5
3
6
19
14
8
1
3
1
2
̮0.03 0.06 0.125 0.25
Isoniazid
MB method
ATP method
Rifampicin
MB method
ATP method
Levofloxacin
MB method
ATP method
Clarithromycin
MB method
ATP method
10
10
MB method
ATP method
Amikacin
MB method
ATP method
7
3
2
5
4
5
10
12
6
3
1
2
4
8
16
̮16
2
6
4
3
4
7
6
4
4
8
10
3
1
7
4
16
5
5
64
128 ̮128
16
32
̮32
3
2
3
1
1
1
32
1
1
3
5
1
̮0.5
Ethionamide
2
8
0.25 mg/ml ῡ MIC Q̰Q῜´Qῠ̮̰Ὶ̯ῗΌQΊ
̰QῙ̰Ὶ̯ῧQQ̯̯̯̯Ῐ̰ῌ
NCCLS ῡ Q Q ̲ Q Q ATCC Q Q ῼ ̯ ̮ ̰ M.
̰῟ῌ ῥ῟QQ̰12)ῗ M. intracellulare ῢ M. avium
avium ATCC 700898 ῡ CAM ῠQ῝̰QQ̲Qῢ῍
ῠQ῜̯ RFP, SM ῞῜̯ KM ῠQ῝̰´QQῗ̳̮
QQ pH 7.3ῒ7.4 ̯ 0.5ῒ2 mg/ml ̯Ί̰̯̮̰ῗ῍
Ὶ̯῍ ̱Q῍ Ύ΅ῳ̱QῠQ῜̯ῢ M. avium ῡQῗ
̳Ὸῡ Q̯ῢ MB Q̯ 0.25 mg/ml, ATP Q̯
M. intracellulare ῠQ῜´QQῗ̳̮̯Q̳῜̯̮
0.125ῒ0.25 mg/ml ̯QQQ̯Q̮Q̰Q῜῟ῌ ῞Ὶ
̰ῌ ῷῐῡ̳Ὸῡ ῶ̯ῧ RFP, SM ῞῜̯ KM ῠ̮
̯ NCCLS ῡQQQ̯̮̰QQ̱Q̲QQ̯QQ̲Q
̮̯῍ M. intracellulare ῢ M. avium ῠQ῜̯Q̮Q
῰ῲῑ῭ (pH 7.3 to 7.4) ̰Q QῠQQ῜῍ Q̰
̰Q῜´Q῿ ῠ̮̯῟ῌ ῜ῖ῜῍ Ύ΅ῳ̱Qῠ̯̮
̳̯῟ῗ MIC Qῢ 0.125ῒ0.25 mg/ml ̰Q῜῍ ̳Ὸ
̯ ῢ 2 ῾ Q ̲ ῠ ΰ ῤ Q Q ῡ MIC Q Q ̰ Q ῜ M.
Q̰̳̯῟ MB Q῍ ATP Q̯Q̰̰̯̮Q̰Q῜
avium ῡQῡ´QQῗ̳̮Ὶ̯ῢQῦ̰̰̯ῖ̯῟ῌ
῟ῌ Ὶ̰ῗQ̮῟ῼῡ̱̲̯ῡῖ῍ ̮̰̮ῢ῞ῡQῡ
ῥ῟῍ MAC ῠQ῝̰´Q῎QQῡQQ`ῲῪῬ῱Ὺ
Q QQῡ̱̲̯ῡῖ̰ Q QQ̯̮̰ῌ ῜ῖ῜῍
̱῭ῗ Heifets13) ῠῩ̯̯Q̱Ί̰̯̮̰ῗ῍ Ὶ̰ῠ
῞ῡQῡ ATCC QQῼ 3 ῼῠ̯̮̯ῢ῍ Q̳̰ῡQ
Ῡ̯̯QQ῝̰̯ M. intracellulare ῢ RFP ̯ CAM
̳11)ῠ ̰̰̰ 7 QQῠῩ̰ BrothMIC NTM ῡQ῵
ῠQῼ´Q̯̮̯῟ῌ M. avium ῢ CAM ῠῢQῼ´
Ί̰῟ MIC QQ̯῍ ῷῐῡ̳Ὸῡ Q ῶ̯ῩῘ̱
Q̯̮̯῟ῗ῍ RFP ῢῨῨQ̮´QQ ΐMB Q῏ 55̮,
Q῜̯̮῟ῌ
ATP Q῏ 70̮῔ ̯̮̯῟ῌ ῞ῡQῡQQ̯ῢ MAC Q
QQQQῼῡ̳῾ΏQ̰Q ῜῟ῗ῍ M. kansasii
ῠQQQQ̯῜̯QQΊ̰̰ SM, EB, AMK ῠ̯̮̯
ῡ RFP ῠQ῝̰ NCCLS ῡQQQQ`ῲῪῬ῱Ὺ̱
ῢ ΐMB Q῏ 22.5ῒ47.5̮, ATP Q῏ 22.5ῒ60̮῔ ῡ
῭ῗ 1 mg/ml ̯̮̰῍ ̳Ὸῡ Q῜῟ῼ̯ῢ 0.125ῒ
´QQ̯̮̯῟ῌ
46 QQQQQQQῺQQ Vol. 14
No. 3
2004.
ATP ῡῩ̰῕ΊῘQ῿QQQ̳̯ῩQ QQQQ̯Qῌ
NTM ̯QῘ῝Q̳Q̯Q̳Ῡ̮Q̯῕QQ῞̯῍
NTM ̯QῘ῝QῘ̮̲̮ῗῧ̰ΰQῗῧ῝῕ῦQ
rifamycin ̰῎Q῍ caprazamycin-B, ketolides Q̯
̯̯ῩQ QQQQ̮ΰ̯̰̰Ὺ̰ῑ`ῑῬῡ̯̯῞
̯̯̰ῩQ῞̯῝ῼῢῚ̰῟̯ῦῢ̯῟QῨῧ῍ QQ
ῡῙῡῙῲQ̯ῖ῵ῗῧῦῩQ QQQQ̮ΰῡῧ
ῦῌ ATP ῡ̯῜Q ῏ῲQ̯΅ ῞QῌῘΊQῪῡ
̯ MB ῡ῟ῢΰ̮Q Ῐ῍ Ῐ̮ῢQQΏ´̮῞῔ῦῖ
῟̮ῤ῍ NTM ̯ῩQ QQQQῡ῟Ῐ῝̰̰῞῔ῦ
῟῝ῼῗῧΊῌ ῡΊ῍ ̳̮̱QῥQ̯̮῏̮ῑῘ῕
NTM ̯ῩQ QQQQ̯῍ ATP ῡῩ̰῕ῦῖ῟̯ΰ
ῥ῍ QQΏῗῧΊ̳ Q̯̮QῩQ̮ῖ῟̮´̮῞῔
ῥ῍ ̮QQ̯QQ̯ῴ̳ῗῧ̯῕ῠῡ῟Ῐ῝̰̰῞῔
ῦῌ
῍ ῌ
1) ΐῤQ῿῞ ̲ῘQQQQ̳QQ̱̱̲῎ 2003.
̮ῘQ῿QQQ̳QQQ̯ ῙῦQ̲ῌ2003 ῔῎
Q῿ 78: 569῍572.
2) ̳QQQ῍ Q῎ 1997. ̳Qῐ ATP QQ̯ΰῦQ
̳Ῡ QQQQ ῒQῒ̯ΐ῎ ΐΏ`̲Q ῒQ 45 ̲
ΐῤΏ `ῡ ̲QῳQΐῐ 146.
3) ̱Q̮̳῍ Q῎ 1997. ATP ῡ̯QQῩ QQQQ
ῠ̯ῷ̰ ῒῚ̯ 3ΐ ῲQ̯΅ Ῡ̰῕ΊQ̰Q̯
῝ῼ῎ ΐΏ`̲Q ῒQ 45 ̲ΐῤΏ `ῡ ̲Qῳ
Qΐῐ 147.
4) QQῬ̰῍ QQQQ῍ ΌQ ῢ῍ Q῎ 1998. Q̯̮
QῩ̰῕ΊQ῿̳̯QQῩQ QQQQῡῌMycobacterium tuberculosis H37Rv Ῡ̰῕Ί QQ
Qῌ῎ ῲQ῞῭ 46: 834῍840.
5) QQῬ̰῍ QQQQ῍ QῺQῧ῍ Q῎ 1999. Q̯̮
QῩ̰῕ΊQ῿̳̯QQῩQ QQQQῡ ῒQ II
̯ΐῐ ῩQ῕Q̯Qῌ̮ΰ̯QQῡ῟̯ῗ ῎ ῲQ
175
῞῭ 47: 170῍175.
6) QQῬ̰῍ QQQQ῍ QῺQῧ῍ Q῎ 2000. Q̯̮
QῩ̰῕ΊQ῿̳̯QQῩQ QQQQῡ ῒQ III
̯ΐῌfilamentous cell treatment ̯ΰῦ ATP ῡ
̯̲῰῎ ῲQ῞῭ 48: 167῍173.
7) Palaci M, et al. 1996. Evaluation of Mycobacteria Growth Indicator Tube for recovery and
drug susceptibility testing of Mycobacterium
tuberculosis isolates from respiratory specimens. J. Clin. Microbiol. 34: 762῍764.
8) QQQ̳῍ QQQ ̰῍ QQ Q῍ Q῎ 1998. Middlebrook QQ̮Q῞̯QQ̳ῩQ QQQQ ῒQ
2 ̯ΐῐ ῩQQQ῰̰̰ῲ΅῱ῑΎῩ̰῕ΊῙ῱ῶ
Q Qῡ῞̯QQ̮̱QQ῕Q̯QQ ῒQῐ 3 Q
Q̯̮̮ῦ̳῍῝ῼΐ῎ ῲQ῞῭ 46: 719῍727.
9) National Committee for Clinical Laboratory
Standards (NCCLS). 2003. Susceptibility Testing of Mycobacteria, Nocardia, and Other Aerobic Actynomycetes; Approved Standard M24A, NCCLS, Wayne, USA.
10) QῨQ̲῍ QQQQ῍ ̯ΌQῦ῎ 2001. Rifalazil,
clarithromycin ̮ΰ̯ levofloxacin ̯ 7HSF ῶ
Q̮QQ̯Q῿̳̮ΰ̯ Mycobacterium avium
̯QῙῦQ̳Q̰̮Q῭̰ῑῳ῎ ΐΏ`̲Q 49:
649῍652.
11) QQQ̳῍ ῸQQΊQ῍ QQ Q῍ Q῎ 2002. Middlebrook QQ̮Q῞̯QQ̳ῩQ QQQQ ῒQ
4 ̯ΐῐ Nontuberculous Mycobacteria ῩQQQ
Q῟ῙῦῙ῱ῶQ Qῡ῍ BrothMIC NTM ̯̲
̮῝ῼ . ῲQ῞῭ 50: 381῍391.
12) QQQQ῍ ῟ΌQῦ῍ QῨQQ῍ Q῎ 2002. Mycobacterium intracellulare ̯̱̯ῦQΎ̯̱ ̯῾
QQ̳Q̯QῙῦ QQ̯῜῕῝῎ ΐΏ`̲Q
50: 232῍235.
13) Heifets. 1996. Susceptibility Testing of Mycobacterium avium Complex Isolates. Antimicrob.
Agents Chemother. 40: 1759῍1767.
ΐῤῲQῙQ̯ QQ Vol. 14
No. 3
2004. 47
176
̯Ὶ̮῔ῌῘ
ῒῌ̯Ὶῖΐῌ῕῞῝̮ῌῐ῜ ̯ῌΊ̯Ῑ̮
Evaluation of Microdilution Susceptibility Test for Nontuberculous
Mycobacteria Using the ATP Method
Masayuki Horikawa1), Isao Nishi1), Masahiro Toyokawa1), Naoki Sato2),
Yutaka Okazawa2), Seishi Asari1)
1)
2)
Clinical Laboratory, Osaka University Hospital
Kyokuto Pharmaceutical Industrial CO., LTD.
We have developed a broth microdilution susceptibility test method for nontuberculous mycobacteria
(NTM); in this test method, adenosine triphosphate (ATP) is measured through bioluminescence, with
viable count as the indicator. We have conducted the basic analysis of the method and compared the
method with the broth microdilution method (MB method) using four ATCC referece strains and 45 clinical
isolates. As a result of the examination of the ATP-measuring method (ATP method), it has been shown
that 30-minute pre-processing at room temperature and extraction at 60῎ for 10 minutes were appropriate
steps. For the ATP method, judgment was made by measuring the relative light unit (RLU) ratio after
culturing the microplate for 5 days, and comparison was made with the MIC value after culturing for 7
days. When the positive values for growth were set to an RLU ratio of ῍0.1 for 7 drugs, that is,
streptomycin, ethambutol, kanamycin, isoniazid, levofloxacin, ethionamide and amikacin, and to an RLU
ratio of ῍0.03 for rifampicin and clarithromycin, the rate of concordance with the MB method was rather
lower (84.4῏) for Mycobacterium kansasii ATCC 12478, whereas 97.8ῌ100῏ concordance rates were
obtained for 3 ATCC reference strains. Regarding clinical isolates, the concordance rates obtained for
Mycobacterium intracellulare, Mycobacterium avium, and M. kansasii were 92.2῏, 97.2῏ and 100῏, respectively. From the above results, we have concluded that the ATP method is useful as a method of testing
drug susceptibility of NTM.
48 ῟̯ῠ̮̯ῗ̯ῑ̮̮ Vol. 14
No. 3
2004.